Pharmaceutical network October 14 days ago, CDE official website shows that Zhejiang Huahai Pharmaceuticals' Alipazine tablet imitation 3 types of listing applications were accepted.
meters of intranet data show that in recent years, China's public medical institutions terminal sales of alecolyte tablets grew rapidly, in 2018 after breaking the 1 billion yuan mark, in 2019 to a new high, of which, Chengdu Kanghong Pharmaceuticals market share is the largest, accounting for nearly 50%.
, the only manufacturers of aluminium-ion tablets are Chengdu Kanghong Pharmaceuticals and Qilu Pharmaceuticals.
In recent years, the sales of end-level alipasium tablets in China's public medical institutions (units: 100 million yuan) Source: Mi-Net China's public medical institutions terminal competition pattern Alipazole tablets are the third generation of antipsychotic drugs. according to
meters of intranet data, in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of alecolytic tablets grew rapidly, in 2018 after breaking the 1 billion yuan mark, in 2019 to a new high, of which Chengdu Kanghong Pharmaceutical market share is the largest, accounting for nearly 50%.
Source: Minet MED2.0 China Drug Review Database At present, the domestic market approved arithpenic tablets have two kinds of alecolyxone tablets and arithpenia tablets, while the alecolyxone chip production enterprises only Chengdu Kanghong Pharmaceuticals and Qilu Pharmaceutical two.
addition, Zhejiang Huahai Pharmaceuticals, Guangdong Dongsan Pharmaceuticals, Dongguan Yang Zhikang Pharmaceuticals to copy 3 categories of submitted applications for listing, in the review and approval (in the drug review center).
source: CDE official website, Mienet database.